Exscientia's next collaboration is in rare diseases

A company that calls itself the world-leading AI-driven drug discovery company has entered into a collaboration with Rallybio, a privately-held USA-based development-stage biotechnology company focused on rare diseases.

UK-based Exscientia, which has partnerships with pharma majors including GlaxoSmithKline (LSE: GSK) and Sanofi (Euronext: SAN), is combining its AI drug discovery platform with Rallybio’s expertise in rare disease drug development to accelerate the discovery of small molecule therapeutics for undisclosed indications.

The joint project is owned equally by Exscientia and Rallybio. Financial terms have not been disclosed.